A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE EXTENT OF EXCRETION, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06865571 USING A 14C-MICROTRACER APPROACH

This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose study of PF-06865571 in healthy male participants to characterize the ADME properties of [14C]PF-06865571 following oral administration; and to evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration of unlabeled PF-06865571 and IV administration of [14C]PF-06865571.

Start Date11 May 2021

Sponsor / Collaborator

Pfizer Inc.

NCT04839393

/ CompletedPhase 1

A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-06882961 AND PF-06865571 IN HEALTHY ADULT PARTICIPANTS (PART A) AND OVERWEIGHT ADULTS OR ADULTS WITH OBESITY WHO ARE OTHERWISE HEALTHY (PART B)

This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants. Part B will evaluate the effect of PF-06882961 on the PK of PF-06865571, as well as the effect of PF-06865571 on the PK of PF-06882961 in overweight adults or adults with obesity who are otherwise healthy.

Start Date05 Apr 2021

Sponsor / Collaborator

Pfizer Inc.

NCT04399538

/ CompletedPhase 2

A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)

The study will evaluate the effect of coadministration of a range of doses of DGAT2i with 1 dose of ACCi, on hepatic steatosis and the ability of DGAT2i to mitigate ACCi-induced elevations in serum triglycerides. The study has a 2-part design with sequential conduct of Part 1 and Part 2 with each part conducted in distinct/separate cohorts of participants. The overall study design, objectives/endpoints, eligibility criteria for both parts is envisioned to be identical, however, data from Part 1 will be used to determine whether to conduct Part 2.

Start Date10 Aug 2020

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Ervogastat

100 Translational Medicine associated with Ervogastat

100 Patents (Medical) associated with Ervogastat

Literatures (Medical) associated with Ervogastat

01 Oct 2025·Lancet Gastroenterology & Hepatology

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

Article

Author: Nakajima, Atsushi ; Takahashi, Hirokazu ; Charlton, Michael ; Alkhouri, Naim ; Darekar, Amanda ; Tacke, Frank ; Wong, Vincent Wai-Sun ; Anstee, Quentin M ; Amin, Neeta B ; Rodriguez, Hector ; Kiszko, Jan

BACKGROUND:

Ervogastat, a diacylglycerol acyltransferase 2 (DGAT2) inhibitor, and clesacostat, an acetyl-coenzyme A carboxylase (ACC) inhibitor, have shown promise in reducing hepatic steatosis. Increased circulating triglycerides, a mechanistic consequence of ACC inhibitors, has been shown to be downregulated by DGAT2 inhibitor co-administration. We assessed the efficacy and safety of ervogastat alone and ervogastat plus clesacostat in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3.

METHODS:

This phase 2 double-blind, double-dummy, randomised study was conducted at 198 clinical sites across 11 countries. A computer-generated randomisation code (random permuted blocks method) was used to allocate patients to treatment groups in equal ratios, and stratified based on degree of fibrosis (F2 vs F3), using an interactive response technology system to ervogastat (25 mg, 75 mg, 150 mg, or 300 mg), ervogastat plus clesacostat (150 mg plus 5 mg or 300 mg plus 10 mg), or placebo, twice daily for 48 weeks. The primary endpoint was the proportion of patients achieving MASH resolution without fibrosis worsening, at least 1 stage fibrosis improvement without MASH worsening, or both, at week 48. Patients were analysed according to the treatment group they were assigned to. The primary endpoint was analysed based on the full analysis set (all randomly assigned patients who took at least one dose of study treatment who provided evaluable baseline biopsy data) in which patients missing a week 48 biopsy were considered non-responders. This completed trial was registered with ClinicalTrials.gov (NCT04321031).

FINDINGS:

Recruitment began June 15, 2020; randomisation was completed Feb 22, 2023, with 255 patients randomly assigned and given treatment (73% of planned sample size; ervogastat 25 mg: N=35; ervogastat 75 mg: N=48; ervogastat 150 mg: N=42; ervogastat 300 mg: N=31; ervogastat 150 mg plus clesacostat 5 mg: N=35; ervogastat 300 mg plus clesacostat 10 mg: N=30; placebo: N=34). 13 (38%) patients in the placebo group achieved the composite primary endpoint, as did 16 (46%) in the ervogastat 25 mg group (difference from placebo in the proportion of patients achieving the primary endpoint 0·08 [90% CI -0·11 to 0·27]), 25 (52%) in the ervogastat 75 mg group (0·14 [-0·04 to 0·32]), 21 (50%) in the ervogastat 150 mg group (0·12 [-0·07 to 0·30]), and 14 (45%) in the ervogastat 300 mg group (0·07 [-0·12 to 0·27]). 23 (66%) patients in the ervogastat 150 mg plus clesacostat 5 mg group (difference from placebo 0·27 [90% CI 0·07 to 0·43]) and 19 (63%) of those in the ervogastat 300 mg plus clesacostat 10 mg group (0·25 [0·04 to 0·42]) achieved the composite primary endpoint. Thus, the primary endpoint was not met by any doses of ervogstat alone, but was met by both dose levels of ervogastat plus clesacostat. All experimental groups showed greater effects on MASH resolution without worsening of fibrosis than with placebo alone; improvement in fibrosis by one stage or more without worsening of MASH was not greater in any experimental group compared with placebo. Most adverse events were mild or moderate in severity and did not increase in frequency or severity with increasing dose; however, ervogastat plus clesacostat was associated with a likely undesirable fasting lipid and apolipoprotein profile. The most common adverse event was inadequate control of diabetes (placebo: 4/34 [12%]; ervogastat 25 mg: 6/35 [17%]; ervogastat 75 mg: 5/48 [10%]; ervogastat 150 mg: 3/42 [7%]; ervogastat 300 mg: 2/31 [6%]; ervogastat 150 mg plus clesacostat 5 mg: 2/35 [6%]; ervogastat 300 mg plus clesacostat 10 mg: 2/30 [7%]). There were no fatal events; 19/255 (7%) patients reported 20 serious adverse events (placebo: 1/34 [3%]; ervogastat 25 mg: 1/35 [3%]; ervogastat 75 mg: 5/48 [10%]; ervogastat 150 mg: 1/42 [2%]; ervogastat 300 mg: 4/31 [13%]; ervogastat 150 mg plus clesacostat 5 mg: 5/35 [14%]; ervogastat 300 mg plus clesacostat 10 mg: 2/30 [7%]).

INTERPRETATION:

The combined efficacy, safety, and tolerability data with ervogastat supports continued investigation for its use in MASH. Larger and longer trials are needed to further assess ervogastat and ervogastat plus clesacostat for MASH treatment.

FUNDING:

Pfizer.

01 Feb 2025·CPT-Pharmacometrics & Systems Pharmacology

Exposure–response modeling of liver fat imaging endpoints in non‐alcoholic fatty liver disease populations administered ervogastat alone and co‐administered with clesacostat

Article

Author: Wojciechowski, Jessica ; Hughes, Jim H. ; Vourvahis, Manoli ; Amin, Neeta B.

Abstract:

Non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis describe a collection of liver conditions characterized by the accumulation of liver fat. Despite biopsy being the reference standard for determining the severity of disease, non‐invasive measures such as magnetic resonance imaging proton density fat fraction (MRI‐PDFF) and FibroScan® controlled attenuation parameter (CAP™) can be used to understand longitudinal changes in steatosis. The aim of this work was to describe the exposure–response relationship of ervogastat with or without clesacostat on steatosis, through population pharmacokinetic/pharmacodynamic (PK/PD) modeling of both liver fat measurements simultaneously. Population pharmacokinetic and exposure–response models using individual predictions of average concentrations were used to describe ervogastat/clesacostat PKPD. Due to both liver fat endpoints being continuous‐bounded outcomes on different scales, a dynamic transform‐both‐sides approach was used to link a common latent factor representing liver fat to each endpoint. Simultaneous modeling of both MRI‐PDFF and CAP™ was successful with both measurements being adequately described by the model. The clinical trial simulation was able to adequately predict the results of a recent Phase 2 study, where subjects given ervogastat/clesacostat 300/10 mg BID for 6 weeks had a LS means and model‐predicted median (95% confidence intervals) percent change from baseline MRI‐PDFF of −45.8% and −45.6% (−61.6% to −31.8%), respectively. Simultaneous modeling of both MRI‐PDFF and CAP™ was successful with both measurements being adequately described. By describing the underlying changes of steatosis with a latent variable, this model may be extended to describe biopsy results from future studies.

01 Oct 2024·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Combined structure-based virtual screening and machine learning approach for the identification of potential dual inhibitors of ACC and DGAT2

Article

Author: Deng, Liangying ; Zhang, Shuran ; Wu, Lixing ; Mi, Nana ; Liu, Yanfeng ; Ding, Feng ; Tong, Huangjin

Acetyl-coenzyme A carboxylase (ACC) and diacylglycerol acyltransferase 2 (DGAT2) are recognized as potential therapeutic targets for nonalcoholic fatty liver disease (NAFLD). Inhibitors targeting ACC and DGAT2 have exhibited the capacity to reduce hepatic fat in individuals afflicted with NAFLD. However, there are no reports of dual inhibitors targeting ACC and DGAT2 for the treatment of NAFLD. Here, we aimed to identify potential dual inhibitors of ACC and DGAT2 using an integrated in silico approach. Machine learning-based virtual screening of commercial molecule databases yielded 395,729 hits, which were subsequently subjected to molecular docking aimed at both the ACC and DGAT2 binding sites. Based on the docking scores, nine compounds exhibited robust interactions with critical residues of both ACC and DGAT2, displaying favorable drug-like features. Molecular dynamics simulations (MDs) unveiled the substantial impact of these compounds on the conformational dynamics of the proteins. Furthermore, binding free energy assessments highlighted the notable binding affinities of specific compounds (V003-8107, G340-0503, Y200-1700, E999-1199, V003-6429, V025-4981, V006-1474, V025-0499, and V021-8916) to ACC and DGAT2. The compounds proposed in this study, identified using a multifaceted computational strategy, warrant experimental validation as potential dual inhibitors of ACC and DGAT2, with implications for the future development of novel drugs targeting NAFLD.

News (Medical) associated with Ervogastat

04 Nov 2025

·www.fiercebiotech.com

Pfizer\'s parade of pipeline cuts: Seagen, BioNTech and MASH programs among 11 axed

Pfizer has put the kibosh on two early-stage programs from its $43 billion Seagen buyout. \n Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated steatohepatitis (MASH) combo.The most advanced clinical program dropped by Pfizer in its latest pipeline update is a phase 3 asset for sickle cell disease (SCD) that came to the pharma via its $5.4 billion acquisition of Global Blood Therapeutics in 2022.This summer, the P-selectin inhibitor inclacumab failed to reduce a painful complication of sickle cell compared to placebo. That late-stage trial had been one of two studies for inclacumab in SCD, with Pfizer terminating the other last year due to “slow recruitment.”When asked about the discontinuation, a Pfizer spokesperson pointed to this summer’s phase 3 miss and the fact that Pfizer still touts osivelotor, the only remaining clinical asset from the Global Blood Therapeutics buyout. The HbS polymerization inhibitor is currently in late-stage development in SCD.Also on the chopping block in the company\'s third-quarter clear-out is a midstage MASH combo. The investigational treatment consisted of DGAT2i inhibitor ervogastat and an acetyl-CoA carboxylase inhibitor called clesacostat. The latter drug was previously shelved by Pfizer in 2020 after being tested as a monotherapy for patients with liver scarring. A little bit later, the pharma revived the asset via the investigational duo, which secured FDA fast track status in 2022 for MASH.Pfizer still has ervogastat listed in its pipeline as a midstage monotherapy for MASH, though no phase 2 trials are listed for the asset alone in the federal registrar ClinicalTrials.gov.As of publication, the drugmaker has not responded to Fierce’s questions about the axed combo.The Nov. 4 pipeline update also features a string of phase 1 culls, including the discontinuation of bispecific molecule PF-08046049, a product previously coded SGN-BB228 from Pfizer’s $43 billion Seagen buyout. The CD228x4-1BB costimulatory antibody was being studied in melanoma and other solid tumors, with primary findings expected for next month, according to ClinicalTrials.gov. The three-part study enrolled 41 patients and is the only trial listed on Pfizer’s pipeline for the bispecific. The drugmaker also put the kibosh on PF-08046045, a CD30-directed antibody-drug conjugate that also came from Seagen. The investigational ADC was being tested in patients with advanced lymphoma.Then there’s a mRNA vaccine that was being advanced with partner BioNTech. Dubbed PF-07911145, the prophylactic vaccine was being assessed for varicella, the herpesvirus that causes chickenpox and shingles.The partners are known for their collaboration on the COVID-19 vaccine Comirnaty. In its pipeline update, Pfizer said it would end development of the Comirnaty vaccine for children aged 6 months through 4 years.This was largely expected as the FDA previously said it might not renew Pfizer\'s pediatric COVID shot authorization and did indeed rescind the emergency use authorization in August.The company’s spokesperson did highlight an ongoing phase 3 trial of a variant-based Comirnaty that started in 2022 . The trial could potentially allow for “a single uniform dose to be administered across approved age ranges” rather than differing dose levels for children, the spokesperson explained.Next up in the discard pile is PF-07314470, an investigational bispecific antibody that Pfizer was hoping could serve as a subcutaneous injection for atopic dermatitis. However, a phase 1 study evaluating the product was terminated in August after enrolling 23 healthy volunteers, according to ClinicalTrials.gov.The study was axed “for business reasons,” with “no safety concerns” prompting the decision, according to the federal database.The early-stage atopic dermatitis study is the only in-human trial for PF-07314470 listed in Pfizer’s pipeline. Pfizer\'s string of third-quarter discontinuations also featured the company\'s bispecific IgG1 antibody coded PF-07826390. The investigational bispecific was being tested in an open-label phase 1 expected to wrap at the end of October. The study recruited nine patients with varying types of solid tumors.Pfizer isn’t studying the asset in any other publicly disclosed trials, according to ClinicalTrials.gov.Also discarded is PF-07941944, a potential respiratory syncytial virus (RSV) infection treatment that was studied in healthy volunteers. A program for complicated urinary tract infections coded CTB+AVP (PF-07612577) is getting the boot, too.On the approved side, Pfizer has stopped development of bladder cancer treatment Padcev in patients with the BCG-unresponsive non-muscle-invasive form of the disease.The pharma didn’t respond to Fierce’s questions regarding the reasoning behind the discontinuations.In total, that leaves 101 pipeline programs, including 30 phase 3 studies, according to Pfizer’s online pipeline updated today.On the pharma’s third-quarter earnings call held Nov. 4, company leaders touted the $1.25 billion deal inked with 3SBio for ex-China rights to a clinical PD-1xVEGF bispecific. The pact was announced in May and puts Pfizer in the running against BioNTech, Merck & Co. and Summit Therapeutics in a hot immuno-oncology field. Meanwhile, the company is undergoing a massive cost-realignment initiative designed to save $7.7 billion through 2027. Part of the plan is to reallocate $500 million in savings toward the pipeline by the end of next year, the pharma said today.And of course, there’s the Metsera deal. CEO Albert Bourla, Ph.D., stood firm on the company’s position that it would be acquiring the next-gen obesity biotech despite a recent surprise offer from Novo Nordisk—an offer Pfizer is suing over.If Pfizer’s efforts are successful, the drugmaker would gain a pipeline led by MET-097i, an injectable GLP-1 receptor agonist that could support monthly dosing. The biotech’s clinical-phase pipeline also features a monthly injectable amylin analog that could be combined with MET-097i, and an oral GLP-1 that is designed to drive more weight loss than small molecules and avoid scalability challenges tied to other oral peptides.

VaccinePhase 1Phase 2Phase 3Acquisition

13 Mar 2024

·www.biospace.com

Ionis’ Antisense Molecule Hits Primary Endpoint in Phase II MASH Trial

Pictured: Illustration depicting a damaged liver/iStock, Mohammed Haneefa Nizamudeen A Phase II clinical trial of Ionis Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis drug candidate has hit its primary endpoint, the company said Wednesday. Investigators randomized 160 people with metabolic dysfunction-associated steatohepatitis (MASH), the liver disease formerly known as nonalcoholic steatohepatitis, to receive placebo or one of three doses of ION224 subcutaneously once a month. Ionis designed the ligand-conjugated antisense medicine to cut production of DGAT2, an enzyme that studies have linked to fatty liver disease. After 51 weeks, the proportion of patients who had MASH histologic improvement without worsening of fibrosis was significantly higher in the top two dose cohorts than in the placebo group. The significant differences caused the trial to meet its primary endpoint. Ionis shared the p values for the successful 90-mg and 120-mg doses—0.015 and less than 0.001, respectively—but is yet to provide a closer look at the primary endpoint data. Subgroup analyses found patients with both F2 and F3 fibrosis, the middle scores on a four-point scarring severity scale, improved after taking ION224. The biotech published some secondary endpoint data. ION224 beat placebo on an endpoint that looked at MASH resolution without worsening of fibrosis, as measured by biopsy. At the highest dose, 44% of patients had a 50% or greater relative reduction in liver steatosis, as measured by imaging, while 3% of people on placebo experienced such an improvement. Ionis also saw a trend favoring ION224 for a liver scarring endpoint. In the high-dose arm, 32% of people had at least a one stage improvement in fibrosis without worsening of steatohepatitis as measured by biopsy, compared to 12.5% of their peers in the placebo cohort. The FDA asks sponsors to show a one stage improvement in fibrosis with no worsening of MASH or the resolution of MASH with no worsening of fibrosis in Phase III clinical trials. The first wave of MASH assets failed to clear that bar but recent studies have fared better, with Madrigal Pharmaceuticals hitting both the endpoints in Phase III. The FDA is set to decide whether to approve Madrigal’s resmetirom by Thursday. The success of resmetirom, a THR-β agonist, in clinical trials is part of a series of events that suggest Ionis will face competition if it delivers its own pivotal study victory and brings ION224 to market. Companies are working on MASH molecules against a range of targets, from Boehringer Ingelheim’s glucagon/GLP-1 receptor dual agonist survodutide to Akero Therapeutics’ FGF21 analog efruxifermin. Other companies are interested in Ionis’ MASH target, DGAT2. Pfizer axed one DGAT2 inhibitor after Phase I but still has another candidate, PF-06865571, in mid-stage development. Data from the Phase II clinical trial are imminent, according to ClinicalTrials.gov. Other companies including Sinew Pharma and Viking Therapeutics are working on DGAT1 inhibitors. Nick Paul Taylor is a freelance pharmaceutical and biotech writer based in London. He can be reached on LinkedIn.

Phase 2Phase 3Phase 1Clinical Result

13 Mar 2024

·www.biospace.com

Ionis’ Antisense Molecule Hits Primary Endpoint in Phase II MASH Trial

Pictured: 3D illustration of a damaged liver/iStoc The biotech announced Wednesday that patients on ION224 had histologic improvement in the liver disease without worsening of fibrosis. Ionis’ mid-stage win comes as the FDA is set to decide whether to approve rival Madrigal’s resmetirom by Thursday. Pictured: Illustration depicting a damaged liver/iStock, Mohammed Haneefa Nizamudeen A Phase II clinical trial of Ionis Pharmaceuticals ’ metabolic dysfunction-associated steatohepatitis drug candidate has hit its primary endpoint, the company said Wednesday. Investigators randomized 160 people with metabolic dysfunction-associated steatohepatitis (MASH), the liver disease formerly known as nonalcoholic steatohepatitis, to receive placebo or one of three doses of ION224 subcutaneously once a month. Ionis designed the ligand-conjugated antisense medicine to cut production of DGAT2, an enzyme that studies have linked to fatty liver disease. After 51 weeks, the proportion of patients who had MASH histologic improvement without worsening of fibrosis was significantly higher in the top two dose cohorts than in the placebo group. The significant differences caused the trial to meet its primary endpoint. Ionis shared the p values for the successful 90-mg and 120-mg doses—0.015 and less than 0.001, respectively—but is yet to provide a closer look at the primary endpoint data. Subgroup analyses found patients with both F2 and F3 fibrosis, the middle scores on a four-point scarring severity scale, improved after taking ION224. The biotech published some secondary endpoint data. ION224 beat placebo on an endpoint that looked at MASH resolution without worsening of fibrosis, as measured by biopsy. At the highest dose, 44% of patients had a 50% or greater relative reduction in liver steatosis, as measured by imaging, while 3% of people on placebo experienced such an improvement. Ionis also saw a trend favoring ION224 for a liver scarring endpoint. In the high-dose arm, 32% of people had at least a one stage improvement in fibrosis without worsening of steatohepatitis as measured by biopsy, compared to 12.5% of their peers in the placebo cohort. The FDA asks sponsors to show a one stage improvement in fibrosis with no worsening of MASH or the resolution of MASH with no worsening of fibrosis in Phase III clinical trials. The first wave of MASH assets failed to clear that bar but recent studies have fared better, with Madrigal Pharmaceuticals hitting both the endpoints in Phase III. The FDA is set to decide whether to approve Madrigal’s resmetirom by Thursday. The success of resmetirom, a THR-β agonist, in clinical trials is part of a series of events that suggest Ionis will face competition if it delivers its own pivotal study victory and brings ION224 to market. Companies are working on MASH molecules against a range of targets, from Boehringer Ingelheim ’s glucagon/GLP-1 receptor dual agonist survodutide to Akero Therapeutics ’ FGF21 analog efruxifermin. Other companies are interested in Ionis’ MASH target, DGAT2. Pfizer axed one DGAT2 inhibitor after Phase I but still has another candidate, PF-06865571, in mid-stage development. Data from the Phase II clinical trial are imminent, according to ClinicalTrials.gov . Other companies including Sinew Pharma and Viking Therapeutics are working on DGAT1 inhibitors. Nick Paul Taylor is a freelance pharmaceutical and biotech writer based in London. He can be reached on LinkedIn .

Phase 2Phase 3Phase 1Clinical Result

100 Deals associated with Ervogastat

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis	Phase 2	China	Pfizer Inc.	15 Jun 2020
Fibrosis	Phase 2	Hong Kong	Pfizer Inc.	15 Jun 2020
Fibrosis	Phase 2	Taiwan Province	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	United States	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	Japan	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	Bulgaria	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	Canada	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	India	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	Poland	Pfizer Inc.	15 Jun 2020
Fibrosis, Liver	Phase 2	Puerto Rico	Pfizer Inc.	15 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04321031 (MIRNA, CTgov)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis \| Fibrosis	256	Placebo	nfqbrzjbqg(qwxlavihow) = gxuhfwlvvj yuxbuekdaz (hvfxkcxwow, vsfnxreptm - zkamppvmnb) View more	-	21 Mar 2025
NCT04866225 (CTgov)	Phase 1	-	6	[14C]PF-06865571 ([14C]PF-06865571 300 mg Oral)	qkplfzeekh(ntvukugwnd) = ailelatffh wkkvlontat (iwwxuzojpt, 16.3) View more	-	31 Jul 2024
NCT04866225 (CTgov)	Phase 1	-	6	PF-06865571 (PF-06865571 300 mg Oral & [14C]PF-06865571 100 μg IV)	qkplfzeekh(ntvukugwnd) = xqlgheaeqm wkkvlontat (iwwxuzojpt, 15.8) View more	-	31 Jul 2024
NCT04399538 (CTgov)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	75	Placebo	wjbmfhcteo(zanflexhnw) = qpqlofbmvg yfqcbpqpxl (vxofsrxsmx, jmfumcuhhq - iyjtmvulkb) View more	-	13 Apr 2023
NCT03776175 (CTgov)	Phase 2	Metabolic dysfunction-associated steatotic liver disease	99	Placebo	frhbjxcfbr(lsqgikusbf) = xrqmzzqqnl hvqjcgwipj (gnxiznxibf, anlikrwnqh - amolxvaiao) View more	-	23 Sep 2020
NCT03513588 (CTgov)	Phase 1	Metabolic Dysfunction Associated Steatohepatitis	48	Placebo	odwhzktexb(bhlshfucod) = fypcsjvulc bmaeqosdrn (cqvvbitxdp, qdtongpwip - lvwxhraeiy) View more	-	13 Mar 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ervogastat

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation